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Abstract
Purpose: The aim of this study was to assess the diagnostic and therapeutic impactof preoperative positron emission tomography and computed tomography(PET/CT) in the initial staging of patients with early-stage breast cancer. Methods:A total of 72 consecutive patients (age: range 24-78 years, mean 51 years), withnewly diagnosed operable breast cancer (Infiltrating Ductal carcinoma: Lobularcarcinoma: Others - 49:15:8) with tumor size 10-65 mm were examinedpreoperatively. All patients underwent conventional assessment imagingmodalities like mammography, breast/axillary ultrasound and PET/CT. Results:PET/CT identified a primary tumor in all but two patients. PET/CT solely detectedunsuspected distant metastases (bones, lung, brain etc) in 9 patients and newprimary cancers (endometrium and lung) in another two patients, as well as 11cases of extra-axillary lymph node involvement. In 6 patients, extra-axillarymalignancy was detected by PET/CT only, leading to an upgrade of initial staging in9% (6/70) and ultimately a modification of planned treatment in 12% (9/70) ofpatients. PET/CT evaluation led 5 patients of stage II A to stage IV, 3 patients ofstage II B to stage IV and 1 patient to Stage IIIB which further modified treatmentplan from an adjuvant to a metastatic approach. Conclusion: PET/CT is a valuabletool to provide information on extra-axillary lymph node involvement, distantmetastases and other occult primary cancers. Preoperative 18F fluorodeoxyglucosePET/CT has a substantial impact on initial staging and on clinical management inpatients with early-stage breast cancer.
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1. IntroductionWorldwide, breast cancer accounts for 22.9% of allcancers (excluding non-melanoma skin cancers) inwomen.1In 2008, breast cancer caused 458,503 deathsworldwide (13.7% of cancer deaths in women).1Prognosis and survival rates for breast cancer varygreatly depending on the cancer type, stage, treatment,and geographical location of the patient. As per AJCC(American joint committee for cancer) tumors less than2cm is included in T1; tumor size of 2-5cm is T2 andmore than 5 cm is T3 stage. Early breast cancerscomprise of T1 and T2 with or without axillary lymphnodal involvement. Breast cancers are notorious fordistant metastases. In presence of lymph nodal orextranodal metastases, treatment protocol changesentirely. Therefore, it is necessary to correctly stage the
patient for optimization of therapy. For initialassessment of primary breast cancer, mammography isstill the most widely utilized modality usuallycomplemented with ultrasound (US) for the evaluationof axillary nodal involvement. Other conventionalimaging modalities commonly offered are chest X ray,axillary ultrasound, computed tomography, and positronemission tomography. Combined positron emissiontomography and computed tomography (PET/CT) haswidely replaced PET as a clinical tool since PET/CT hasdemonstrated diagnostic superiority compared withPET alone.2,3For initial and recurrent breast cancerstaging, PET/CT is found to be more accurate thanconventional imaging methods in detectingextra-axillary nodal involvement and distant
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metastases.4-9 In a prospective study of 60 patients withlarge (>3 cm) primary breast tumors, it was shown thatPET/CT changed the initial staging in 42% of patients,but so far other studies published have beenretrospective in nature.5 Therefore, the role of PET/CTin the initial staging of breast cancer remains unclear.The purpose of the present study was to prospectivelyassess the clinical impact of preoperative PET/CT in theinitial staging of newly diagnosed early breast cancerand to evaluate the potential role of PET/CT in futuremanagement of breast cancer patients.
2. Methods and Materials
2.1. Patient PopulationFrom January 2009 to May 2012, 72 consecutivepatients (age range 24-78 years, mean 51years,histology infiltrating ductal carcinoma: lobularcarcinoma: others - 49:15:8) with newly diagnosedbreast cancer scheduled for surgery were included inthis prospective study. None of the patients receivedanticancer therapy or were subjected to curativesurgery prior to PET/CT. Patients were subjected toclinical examination and those with operable tumor ofmore than 2 cm with no clinical suspicion of bilateralcancer, metastases or N3 nodal disease at the time ofdiagnosis were included. Patients with inflammatorybreast cancer, pregnant women as well as patientssuffering from uncontrolled diabetes, claustrophobiawere excluded. The diagnosis of breast cancer wasconfirmed by histopathology in all patients and the stageof cancer was assessed by physical examination,mammography, US of the chest wall and axilla and chestX-ray. All study participants provided written informedconsent before inclusion.
2.2. PET/CT imagingAll 18F FDG PET/CT scans were carried out using a GEDiscovery BGO PET/CT scanner (GE Medical Systems).Patients fasted for at least 6 h before i.v. injection of 370MBq FDG in the antecubital vein contralateral to thebreast cancer. After the FDG injection, patients wereencouraged to drink small quantities of oral contrastmedia (500ml, Ioversol, Optiray-350, Ttco health careCanada,7500, Ponite Claire Quebec).Imaging was carriedout 60 min after the administration of FDG in emptybladder. Patients are positioned supine with their armsraised over their heads. Simultaneous contrast enhancedwhole body CT images with a breath held CT wereobtained from the PET/CT scanner just prior to PETacquisition with the multidetectoreight-slice spiral CTscanner. With a prescan start delay of 40 s, i.v. contrastmedia was injected with an automatic injection system(Cincinnati, Ohio,9000 ADV,Lieberl-Flarsheim).Whole-body PET scan was acquired from the head tomid-thigh using eight axial fields of view with anacquisition time of 3 min per bed position. The CT datawere used for attenuation correction of the PET data.
Both image sets were reconstructed in axial, coronal,and sagittal images with a slice thickness of 3 mm. Anuclear medicine physician and a radiologist incollaboration interpreted the PET and the fused PET/CTimages. The effective radiation dose for the PET/CT scanwas 18 mSv with 8 mSv from the FDG dose and 10 mSvfrom the CT scan.10
2.3. Image interpretationThe PET/CT images were analyzed visually. Themaximum standardized uptake value (SUV max) fromthe primary tumor was used for further analysis. SUV isa semiquantitative analysis of radiotracer uptake and isdefined as the ratio of radiotracer activity per milliliterof tissue to the activity in the injected dose corrected fordecay and the patient’s body weight.11 Except for theprimary tumor site, all foci with pathologic FDG uptakehigher than liver activity were reported as positive andsuspicious for malignancy if the uptake was focal andrelated to anatomical structures or pathological findingson the corresponding CT slices. More diffusepathological sites of uptake with SUV of less than 2.5was reported as non-malignant inflammatory changesand therefore reported as negative.
2.4. Standard of referenceDistant metastases/new primary cancers wereconfirmed histologically by biopsy. Where biopsy wasnot possible or feasible, follow-up PET/CT or otherimaging modalities was used as reference.
2.5. Statistical methodsSensitivity and specificity were calculated usingstandard methods. Sensitivity and specificity measuresthe proportion of correctly identified positives andnegatives, respectively.
3. ResultsA total of 72 consecutive patients with newly diagnosedbreast cancer were included in this study. Patient andtumor characteristics in our study group are listed inTable 1.PET/CT identified the primary tumor in 70/72 patientswith a sensitivity of 97%. The two PET-negative tumorswere either invasive ductal (n=1, size: 22 mm) orinvasive lobular carcinoma (n = 1, size: 15 mm). PET/CTdetected 14/72 patients with axillary lymph nodemetastases. One case proved to be false positive for FDGPET as there were no malignant cells on pathologicalexamination. Extra-axillary lymph node involvementwas diagnosed in 6 patients by PET/CT in the internalmammary chain (n= 4) and supraclavicular region(n=2). PET/CT detected 8 sites of distant metastases innine patients (13%), comprising bone (n=4) (Figure 1),ovary (n=1), lung(n=2) and liver (n=1) metastases(Figure 2). Of these 8 cases, histological examinationrevealed 2 of them to be new cases of co existing
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primary cancers in lung (adenocarcinoma, stage Ib) andin ovary instead of distant metastases.Nine patients had distant metastases which wereconfirmed by either biopsy or other imaging methods.Clinical follow up was done in those cases where biopsysite was not feasible or accessible. In total, 15 sites ofextra-axillary metastases in 9 patients were detected byPET/CT only (Table 2) leading to upgradation of initialstaging in 13% (9/70) of patients and modification ofplanned treatment in 10% (7/70) of patients (Table 2).PET/CT evaluation led 5 patients of stage II A to stage IV,3 patients of stage II B to stage IV and 1 patient to Stage
IIIB which further modified treatment plan from anadjuvant to a metastatic approach (Table 3). Thestandard treatment of early stage breast carcinoma ismodified radical mastectomy followed by adjuvantchemotherapy. Out of 9 patients, 5 patients PET/CT notonly upstaged breast cancer but modified managementalso. 5 patients were shifted to metastatic approach(chemotherapy is offered first to patients) from adjuvanttreatment (Table 3), bisphophonate included andreferred for irradiation if required (Table 3 patientnumber 7).
Figure 1: 18-F FDG PET/CT reported focal abnormal FDG uptake in lytic lesions in bilateral iliac bones. (SUV Max 7.4).
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Figure 2: 18-F FDG PET/CT reported focal abnormal FDG uptake in hypodense lesion in segment II of liver (SUV Max 10.9).
Volume 4 • Number 4 • 2016 International Journal of Cancer Therapy and Oncology 5
www.ijcto.org
©Tewari et al. ISSN 2330-4049
Table 1: Various factors in patient and tumor characteristics.Characteristics Subdivisions Initial patientpopulation Patient populationwith change inmanagementAge(years) MeanRange 5124-78 4029-51Histopathology Infiltrating DuctalcarcinomaLobular carcinomaOthers
49158
243Tumor size (mm) MeanRange 3810-65 4424-64ER +ve-ve 5220 54PR +ve-veUnknown 40302 252HER 2 +ve-ve 1854 27SUV max (gm/ml) MeanRange 19.31.2-36.2 31.313.2-36.2
Table 2: Sites of distant metastases detected by 18 F-FDG PET/CT which further changed initial TNM staging of primarypreoperative breast malignancy.Patient no PET/CT-positive disease Initial stage Final stage1 Bone metastases T2N0M0 T2N0M12 Internal  mammary LN T2N1M0 T2N3M03 Ovaries, bone and  internal mammary LN T2N1M0 T2N3M14 Supraclavicular LN T2N1M0 T2N3M05 Internal mammary LN and lung T2N1M0 T2N3M16 Bone metastasis T2N1M0 T2N1M17 Internal mammary LN and bone T2N1M0 T2N3M18 Liver metastases T2N0M0 T2N0M19 Supraclavicular  LN T1N1M0 T1N3M0
Table 3: Upstaging of primary breast malignancy in 9 patients along with modification in management.Patient no. Initial stage Final stage Treatment Modification1 Stage IIA Stage IV Adjuvant to a metastatic approach.Bisphosphonate was included2 Stage IIB Stage III C Irradiation if axillary LN positive3 Stage II A Stage III C Adjuvant to a metastaticapproach.Abisphosphonate was included4 Stage II B Stage III C None5 Stage II A Stage IV Adjuvant to a metastaticapproach.6 Stage II A Stage IV Adjuvant to a metastatic approach.Bisphosphonate was included7 Stage II B Stage IV Adjuvant to a metastatic approach.Focused irradiation was included8 Stage IIA Stage IV Additional surgery and adjuvantchemotherapy of the tumors.9 Stage II A Stage IIIB None
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4. DiscussionDiscussions The purpose of this study was toprospectively assess the role of preoperative FDGPET/CT in the initial staging of cT2-3 breast cancer. Inpatients with breast cancer, correct staging of thedisease is mandatory to select the correct treatmentprotocol. For the tumor localized to extra nodal ordistant metastases, patient are treated with adjuvanttherapy, surgery followed by chemotherapy, but locallyadvanced tumors, advanced axillary dissemination withthe evidence of distant metastases treatment protocolchanges from curative to palliative approach. Thesepatients are commonly treated with neoadjuvantchemotherapy followed by definitive surgery, postoperative chemotherapy and external radiation.Henceforth accurate initial staging of patients withbreast cancer is essential for precise prognosticationand optimal choice of therapy. 18-Fluorodeoxyglucose(18-FDG) PET demonstrates abnormal metabolicfeatures associated with malignancy that often precedemorphologic findings demonstrated with anatomicimaging. Positron emission tomography (PET) andPET/computed tomography (CT) are increasingly usedfor oncologic imaging. Combined PET/CT allows moreprecise anatomic localization of PET abnormalities andhas been shown to improve diagnostic accuracy.12 In ourstudy, PET/CT solely detected distant metastases(bones, lung, liver etc) in 9 patients and new primarycancers (endometrium and lung) in another twopatients. In 6 patients, extra-axillary metastases wasdetected by PET/CT only, leading to an upgrade of initialstaging in 9% (6/70) and ultimately a modification ofplanned treatment in 12% (9/70) of patients. In presentstudy, PET/CT evaluation led 5 patients of stage II A tostage IV, 3 patients of stage II B to stage IV and 1 patientto Stage IIIB. In previous studies, PET/CT led to a changein stage in up to 42% of cases, resulting in a change ofpatient management in 13%–32% of cases.5, 8, 14, 15 Instudies with a 42% change of stage, a substantial part ofthe changes were due to axillary lymph node metastasesdetected by PET/CT only,14which accounts for the largedifference in patients with a change of stage detected byPET/CT only as shown in this study. Reasons for therelative variation in frequency of change of treatment inthis study could be due to the differences in selection ofpatients. Several earlier studies included more high-riskand heterogeneous populations.15In present study, PET/CT reported two synchronous coexisting primary malignancies; lung adenocarcinomaand other being endometrial carcinoma. The incidentaldetection of coexisting primary tumors has beenreported in previous PET/CT studies [16] and it is wellestablished that cancer patients have a higher risk andhigher incidence of co existing dual or new primarytumors. From the two examples in our study, it isplausible that the early detection of the new primarycancer is beneficial to patients. Patient identified with
primary lung cancer received curative surgery with noadjuvant treatment and is still recurrence free >25months after diagnosis whereas other patient diagnosedwith endometrial/ovary cancer received both primarysurgery (oopho-hysterectomy) and adjuvantchemotherapy and is also recurrence free >27 monthsafter diagnosis.In our study, a significant proportion of patients werefound to have extra-axillary metastases thatsubsequently led to modification of treatment.17,18Whether or not a change in disease stage, the treatmentat initial assessment leads to a survival benefit isunknown and also requires further studies.
5. Conclusionin this study, we found that FDG PET/CT is a valuabletool to provide information on extra axillary lymph nodeinvolvement, distant metastases and other occultprimary cancers. In the initial stage assessment,preoperative FDG-PET/CT has a substantial impact onstaging and on clinical management and we suggest thatPET/CTcould be considered in the initial assessment ofpatients with newly diagnosed node-positive early-stagebreast cancer >2 cm.
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